Gui Yang, Ye Lifang, Wu Liuyang, Mai Haohui, Yan Qiqi, Wang Lihong
BengBu Medical College, Bengbu, China.
Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Front Cardiovasc Med. 2022 Feb 11;9:707148. doi: 10.3389/fcvm.2022.707148. eCollection 2022.
His-Purkinje system pacing has recently emerged as an alternative to biventricular pacing (BIVP) in cardiac resynchronization therapy (CRT). The aim of this study was to conduct a meta-analysis comparing the clinical outcomes associated with His-Purkinje system pacing (HPSP) vs. BIVP in patients with heart failure. There is also a comparison of clinical outcomes of His-bundle pacing (HBP) and left bundle branch pacing (LBBP) in the His-Purkinje system.
We searched the Cochrane Library, Embase, and PubMed, for studies published between January 2010 and October 2021 that compared the clinical outcomes associated with HPSP vs. BIVP and HBP vs. LBBP in HPSP in patients who underwent CRT. The pacing threshold, R-wave amplitudes, QRS duration, New York Heart Association functional (NYHA), left ventricular ejection fraction (LVEF), and LV end-diastolic diameter (LVEDD) of heart failure, at follow-up, were extracted and summarized for meta-analysis.
A total of 18 studies and 1517 patients were included in our analysis. After a follow-up period of 9.3 ± 5.4 months, the HPSP was found to be associated with shorter QRS duration in the CRT population compared to that in the BIVP (SMD, -1.17; 95% CI, -1.56 to -0.78; < 0.00001; I = 74%). No statistical difference was verified between HBP and LBBP on QRS duration (SMD, 0.04; 95% CI, -0.32 to 0.40; = 0.82; I = 84%). In the comparison of HPSP and BIVP, the LBBP subgroup showed improved LVEF (SMD, 0.67; 95% CI, 0.42-0.91; < 0.00001; I = 0%), shorter LVEDD (SMD, 0.59; 95% CI, 0.93-0.26; = 0.0005; I = 0%), and higher New York Heart Association functional class (SMD, -0.65; 95% CI, -0.86 to -0.43; < 0.00001; I = 45%). In terms of pacing threshold and R-wave amplitude clinical outcomes, LBBP has a lower pacing threshold (SMD, 1.25; 95% CI, 1.12-1.39; < 0.00001; I = 47%) and higher R-wave amplitude (MD, -7.88; 95% CI, -8.46 to -7.31; < 0.00001; I = 8%) performance compared to HBP.
Our meta-analysis showed that the HPSP produced higher LVEF, shorter QRS duration, and higher NYHA functional class in the CRT population than the BIVP as observed on follow-up. LBBP has a lower pacing threshold and higher R-wave amplitude. HPSP may be a new and promising alternative to BIVP in the future.
在心脏再同步治疗(CRT)中,希氏-浦肯野系统起搏最近已成为双心室起搏(BIVP)的一种替代方法。本研究的目的是进行一项荟萃分析,比较心力衰竭患者中希氏-浦肯野系统起搏(HPSP)与BIVP相关的临床结局。同时也比较了希氏束起搏(HBP)和左束支起搏(LBBP)在希氏-浦肯野系统中的临床结局。
我们检索了考克兰图书馆、Embase和PubMed,查找2010年1月至2021年10月期间发表的比较接受CRT患者中HPSP与BIVP以及HPSP中HBP与LBBP相关临床结局的研究。提取并汇总随访时心力衰竭患者的起搏阈值、R波振幅、QRS时限、纽约心脏协会功能分级(NYHA)、左心室射血分数(LVEF)和左心室舒张末期直径(LVEDD),进行荟萃分析。
我们的分析共纳入18项研究和1517例患者。在9.3±5.4个月的随访期后,发现与BIVP相比,CRT人群中HPSP与更短的QRS时限相关(标准化均数差,-1.17;95%可信区间,-1.56至-0.78;P<0.00001;I² = 74%)。HBP和LBBP在QRS时限方面未证实有统计学差异(标准化均数差,0.04;95%可信区间,-0.32至0.40;P = 0.82;I² = 84%)。在HPSP与BIVP的比较中,LBBP亚组显示LVEF改善(标准化均数差,0.67;95%可信区间,0.42 - 0.91;P<0.00001;I² = 0%),LVEDD更短(标准化均数差,0.59;95%可信区间,0.93 - 0.26;P = 0.0005;I² = 0%),以及纽约心脏协会功能分级更高(标准化均数差,-0.65;95%可信区间,-0.86至-0.43;P<0.00001;I² = 45%)。在起搏阈值和R波振幅临床结局方面,与HBP相比,LBBP的起搏阈值更低(标准化均数差,1.25;95%可信区间,1.12 - 1.39;P<0.00001;I² = 47%)且R波振幅更高(平均差,-7.88;95%可信区间,-8.46至-7.31;P<0.00001;I² = 8%)。
我们的荟萃分析表明,随访时CRT人群中HPSP比BIVP产生更高的LVEF、更短的QRS时限和更高的NYHA功能分级。LBBP具有更低的起搏阈值和更高的R波振幅。未来HPSP可能是BIVP一种新的且有前景的替代方法。